Novavax expects COVID-19 vaccine U.S. data from trial in Q2

FILE PHOTO: A Novavax logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) – Novavax Inc said on Monday it expects to report U.S. data from a late-stage study testing its COVID-19 vaccine candidate in the second quarter of this year.

The company said it intends to file for authorization with the U.S. Food and Drug Administration, the UK Medicines and Healthcare products Regulatory Agency and the European Medicines Agency in Europe in the third quarter of 2021. (

Source: Read Full Article